Canada markets closed

BriaCell Therapeutics Corp. (BCT.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.0800-0.0200 (-0.95%)
At close: 12:11PM EDT
Full screen
Previous Close2.1000
Open2.0700
Bid2.0000 x N/A
Ask2.0900 x N/A
Day's Range2.0300 - 2.0800
52 Week Range1.8000 - 10.1982
Volume7,725
Avg. Volume10,121
Market Cap38.032M
Beta (5Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-1.0800
Earnings DateJun 10, 2024 - Jun 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

    PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,9

  • GlobeNewswire

    BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

    PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common share

  • GlobeNewswire

    BriaCell Announces Oral and Poster Presentations at ASCO 2024

    Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca